Bhringaraj for Hair Growth - Quick Reference Sheet
evipedia.ai
← Back

Bhringaraj for Hair Growth

Created on 09/19/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A traditional Indian scalp-oil herb with strong laboratory but thin human evidence. Extracts push resting follicles back into growth in animals and cells; the only human hair study tested a multi-herb oil with no inactive comparison. Skin reactions and blocked pores are modest and mostly avoidable; toxic metal in Ayurvedic products is the larger hazard. (Full Review)

Protocol

Standard topical oil regimen
5–10 mL, 2–3× weekly
Bhringaraj-infused coconut or sesame oil, left on one to two hours or overnight.
Powder paste alternative
10–20 g, 30–45 min
Dried leaf powder in water or yoghurt; for scalps too oily for leave-on oil.
Oral whole-leaf approach
3 g/day for 60 days
Dried leaf in divided capsules, the only orally tested amount.
Time to effect
Blood pressure and cholesterol
60 days
Measurement point of the only oral trial. Not central to hair growth.
Hair density, thickness and growth rate
120 days
The hair cycle sets the floor; earlier change reflects shine, not growth.
Premature greying and scalp flaking
120 days
Both scored at Day 120 in the same oil study. Not central to hair growth.

Benefits

Contraindications
  • Pregnant and breastfeeding individuals, both routes
  • Known Asteraceae, ragweed, chrysanthemum or feverfew contact allergy, or a positive sesquiterpene lactone mix patch test
  • Chronic kidney disease at estimated glomerular filtration rate below 30 mL/min/1.73 m², oral use
  • Child-Pugh Class B or C liver disease (moderate to severe cirrhosis), oral use
  • Treated low blood pressure, or an untreated resting systolic pressure below 100 mmHg, oral use
  • Children under 12, either route
  • Blood lead level above 5 µg/dL from any source
  • Active scalp infection, open scalp wounds or scarring alopecia, topical use
    •
Key Interactions
  • Antihypertensives and diuretics (amlodipine, lisinopril, hydrochlorothiazide): caution with oral use
  • Glucose-lowering medication (metformin, glipizide, insulin): monitor with oral use
  • UGT1A1 substrates with narrow margins (irinotecan, raltegravir, dolutegravir): caution, theoretical
  • Topical minoxidil: no interaction identified
  • Over-the-counter anti-inflammatories (ibuprofen, naproxen) and decongestants (pseudoephedrine): monitor
  • Over-the-counter antifungal shampoos (ketoconazole, selenium sulfide, zinc pyrithione): monitor
  • Other Asteraceae supplements (milk thistle, chamomile, echinacea, arnica): caution
  • Supplements with additive blood-pressure lowering (beetroot nitrate, hibiscus, garlic extract, potassium): caution with oral bhringaraj
  • Other interventions: microneedling and scalp injections, caution; permanent hair dye, monitor

Risk & Side Effects

  • Medium: Blood pressure drop and increased fluid loss with oral use; heavy-metal contamination of Ayurvedic bhringaraj products
  • Low: Allergic contact dermatitis to the daisy family; oil-induced acne and folliculitis from heavy scalp application
  • Speculative: Lowered blood glucose; oestrogen-like activity of the coumestan class; competition for liver glucuronidation enzymes

Monitoring

Marker Target Why
Serum ferritin 70–100 ng/mL in women, 100–150 ng/mL in men Low iron stores sustain shedding and mask any regrowth
25-hydroxyvitamin D 40–60 ng/mL Deficiency is associated with disordered follicle cycling
TSH 0.5–2.0 mIU/L Both under- and overactive thyroid cause diffuse loss that mimics pattern loss
Seated blood pressure 110–125 / 70–80 mmHg Oral bhringaraj lowers mean arterial pressure and raises urine output
ALT and AST ALT 10–26 U/L, AST 10–26 U/L Detects liver injury from a herbal preparation or from metal contamination
Venous blood lead Below 1.0 µg/dL; no threshold is considered safe Ayurvedic preparations carry a documented lead burden
Serum potassium and sodium Potassium 4.0–4.5 mmol/L, sodium 138–142 mmol/L Oral use increases urinary sodium loss
Hair density by trichoscopy No established target; track change from the individual's own baseline at a marked scalp point The only direct readout of whether anything is happening

Cadence: Baseline before starting. Imaging and shedding counts at four and eight months. Blood pressure weekly for the first month of oral dosing, then monthly. Liver enzymes and lead at three months, then every six to twelve months while oral use continues. Topical-only use needs no routine blood work beyond the baseline.

Qualitative Assessment

  • Hairs recovered from a standard 60-stroke comb on a fixed day of the week
  • Scalp comfort: itch, burning, tightness or stinging after application
  • Hair texture, shine and manageability, which change long before density does
  • Side-by-side photographic impression under identical lighting and parting
  • Lightheadedness on standing, as an early signal of the pressure and fluid effect during oral use
  • Energy levels and sleep quality, which track the nutritional and thyroid factors that drive shedding
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.